Atara Biotherapeutics Inc. (ATRA) and Kura Oncology Inc. (NASDAQ:KURA) Contrasting side by side

This is therefore a comparing of the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation in Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Kura Oncology Inc. (NASDAQ:KURA). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atara Biotherapeutics Inc. N/A 0.00 186.00M -4.63 0.00
Kura Oncology Inc. N/A 0.00 55.10M -1.67 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Atara Biotherapeutics Inc. and Kura Oncology Inc.


Table 2 provides us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Atara Biotherapeutics Inc. 0.00% -50.5% -45.7%
Kura Oncology Inc. 0.00% -44.8% -39.5%


13.8 and 13.8 are the respective Current Ratio and a Quick Ratio of Atara Biotherapeutics Inc. Its rival Kura Oncology Inc.’s Current and Quick Ratios are 14.8 and 14.8 respectively. Kura Oncology Inc. has a better chance of clearing its pay short and long-term debts than Atara Biotherapeutics Inc.

Analyst Recommendations

The next table highlights the shown recommendations and ratings for Atara Biotherapeutics Inc. and Kura Oncology Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Atara Biotherapeutics Inc. 0 0 1 3.00
Kura Oncology Inc. 0 0 0 0.00

Atara Biotherapeutics Inc.’s upside potential currently stands at 58.04% and an $62 consensus target price.

Insider and Institutional Ownership

Atara Biotherapeutics Inc. and Kura Oncology Inc. has shares owned by institutional investors as follows: 0% and 77.3%. 3.3% are Atara Biotherapeutics Inc.’s share owned by insiders. Insiders Competitively, owned 10.8% of Kura Oncology Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Atara Biotherapeutics Inc. 7.56% 16.64% 8.1% 0.28% 213.65% 137.4%
Kura Oncology Inc. 8.82% 14.31% -26.88% -19.18% -2.33% -9.67%

For the past year Atara Biotherapeutics Inc. has 137.4% stronger performance while Kura Oncology Inc. has -9.67% weaker performance.


Kura Oncology Inc. beats on 5 of the 7 factors Atara Biotherapeutics Inc.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. Its clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. The company is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company also has a clinical trial collaboration agreement with Merck Sharp & Dohme B.V. to evaluate ATA129 in combination with Merck anti-programmed death receptor-1 therapy and Keytruda in patients with platinum resistant or recurrent epstein-barr virus-associated nasopharyngeal carcinoma. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companyÂ’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.